Brent Hendricks visited StoryCorps in Atlanta with his mother, Barbara.
May 1, 2015 Sixty years ago, most children with cystic fibrosis didn't live past the age of 5. Today most with the disease live into their 40s. Brent Hendricks says it is "like being on a boat with a hole in it."
<iframe src="http://www.npr.org/player/embed/403303311/403474906" width="100%" height="290" frameborder="0" scrolling="no">
Kalydeco is one of the first drugs that is effective at combating the root causes of a genetic disease.
Vertex Pharmaceuticals Inc.
January 2, 2013 The success of Kalydeco, a drug to treat cystic fibrosis, has been decades in the making — since the discovery of the gene associated with the disease. The time from gene discovery to successful drug may be shortening, but there are only a handful of drugs like Kalydeco on the market.
<iframe src="http://www.npr.org/player/embed/168353348/168486135" width="100%" height="290" frameborder="0" scrolling="no">
February 1, 2012 The Food and Drug Administration approved the first drug that treats cystic fibrosis by addressing an underlying cause of the disease. But the medicine, called Kalydeco, will cost nearly $300,000 a year.
<iframe src="http://www.npr.org/player/embed/146166743/146188070" width="100%" height="290" frameborder="0" scrolling="no">
February 25, 2011 On this week's show, we talk about results of a national poll that show confusion about the federal health law, plus health care woes from Tennessee and Pennsylvania. And we bring you two stories of exercise improving the health of seniors — from their muscles to their minds.
<iframe src="http://www.npr.org/player/embed/134057454/134069757" width="100%" height="290" frameborder="0" scrolling="no">
February 24, 2011 An experimental medicine, taken twice a day, dramatically improved breathing in people whose cystic fibrosis stems from a particular genetic defect. If approved by the Food and Drug Administration, the medicine could be very pricey.
NPR thanks our sponsors
Become an NPR sponsor